Venus Remedies Limited — Cytarabine Exporter Profile
Indian Pharmaceutical Exporter · #9 for Cytarabine · $186.7K export value · DGFT Verified
Venus Remedies Limited is the #9 Indian exporter of Cytarabine with $186.7K in export value and 18 verified shipments. Venus Remedies Limited holds a 1.7% market share in Cytarabine exports across 7 countries. The company exports 29 pharmaceutical products worth $86.4M across 6 therapeutic categories.
Venus Remedies Limited — Cytarabine Export Profile: Buyers & Destinations
Where Does Venus Remedies Limited Export Cytarabine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| TUNISIA | $111.6K | 7 | 59.8% |
| COLOMBIA | $47.0K | 3 | 25.2% |
| PHILIPPINES | $17.6K | 1 | 9.4% |
| VENEZUELA | $4.2K | 2 | 2.2% |
| KUWAIT | $3.8K | 2 | 2.0% |
| ZIMBABWE | $2.5K | 1 | 1.4% |
| SAUDI ARABIA | $0 | 2 | 0.0% |
Venus Remedies Limited exports Cytarabine to 7 countries. The largest destination is TUNISIA accounting for 59.8% of Venus Remedies Limited's Cytarabine shipments, followed by COLOMBIA (25.2%) and PHILIPPINES (9.4%). These destinations reflect Venus Remedies Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Cytarabine from Venus Remedies Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| P C D T PHARMACIE CENTRALE DE | TUNISIA | $45.5K | 2 |
| P.C.D.T | TUNISIA | $33.3K | 2 |
| P C D T | TUNISIA | $32.7K | 2 |
| A.S.A.S | COLOMBIA | $20.7K | 1 |
| 2 M I | PHILIPPINES | $17.6K | 1 |
| ALPHARMA S A S | COLOMBIA | $13.5K | 1 |
| A S A S ALPHARMA SASDESCARGUE DIRECTO | COLOMBIA | $12.8K | 1 |
| C D R B G | VENEZUELA | $4.2K | 2 |
| M O H | KUWAIT | $3.7K | 1 |
| P P C P L | ZIMBABWE | $2.5K | 1 |
Venus Remedies Limited supplies Cytarabine to 13 buyers globally. The largest buyer is P C D T PHARMACIE CENTRALE DE (TUNISIA), followed by P.C.D.T (TUNISIA) and P C D T (TUNISIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Cytarabine Export Value and How Much Does Venus Remedies Limited Contribute?
India exported $9.8M worth of Cytarabine through 1,825 shipments from 175 suppliers to 110 countries, serving 381 buyers globally. Venus Remedies Limited contributes $186.7K to this total, accounting for 1.7% of India's Cytarabine exports. Venus Remedies Limited ships Cytarabine to 7 countries through 13 buyers.
What Is the Average Shipment Value for Venus Remedies Limited's Cytarabine Exports?
Venus Remedies Limited's average Cytarabine shipment value is $10.4K per consignment, based on 18 shipments totaling $186.7K. The largest destination is TUNISIA (59.8% of Venus Remedies Limited's Cytarabine exports).
How Does Venus Remedies Limited Compare to Other Indian Cytarabine Exporters?
Venus Remedies Limited ranks #9 among 175 Indian Cytarabine exporters with a 1.7% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($5.1M), FRESENIUS KABI ONCOLOGY LIMITED ($1.8M), NAPROD LIFE SCIENCES PRIVATE LIMITED ($557.0K). Venus Remedies Limited processed 18 shipments to 7 destination countries.
What Cytarabine Formulations Does Venus Remedies Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CYRABOL 1000 MG CYTARABINE FOR INJECTION USP 1000 MG | $71.5K | 2 |
| CYRABOL 1000 MG CYTARABINE FOR INJECTION USP 1000 MG | $28.6K | 1 |
| ALDACIT 500MG CYTARABINE FOR INJECTION USP 500 MG EACH VIAL CONTAINS: CYTARABINEUSP 500 MG | $20.7K | 1 |
| CYTAGET 500MG CYTARABINE SOLUTION FOR INJECTION USP 500 MG/5ML | $17.6K | 1 |
| CYRABOL 500 MG CYTARABINE FOR INJECTION | $13.5K | 1 |
| CYRABOL 500 MG CYTARABINE FOR INJECTIONUSP 500 MG | $12.8K | 1 |
| CYRABOL 100 MG CYTARABINE FOR INJECTIONUSP 100 MG | $7.2K | 2 |
| CYRABOL 100 MG CYTARABINE FOR INJECTIONUSP 100 MG | $4.2K | 1 |
| CYTARABINE FOR INJECTION USP 1000 MG CYRABOL 1.0 GM BATCH NO. X4ACT013A, MFG. DT. 01/2024, EXP. DT. 12/2025 | $3.7K | 1 |
| CYRABOL 500 MG CYTARABINE LYOPHILIZED POWDER FOR INJECTABLE SOLUTION 500MG | $2.8K | 1 |
Venus Remedies Limited exports 16 distinct Cytarabine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CYRABOL 1000 MG CYTARABINE FOR INJECTION USP 1000 MG with 2 shipments worth $71.5K.
How Does Venus Remedies Limited Compare to Nearest Cytarabine Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | UNITED BIOTECH PRIVATE LIMITED | $303.8K | 116 | 13 | $2.6K |
| 8 | MEDORBIS TRADE LLP | $199.1K | 10 | 1 | $19.9K |
| 9 | VENUS REMEDIES LIMITED ★ | $186.7K | 18 | 7 | $10.4K |
| 10 | NV REMEDIES PRIVATE LIMITED | $181.6K | 9 | 3 | $20.2K |
| 11 | PLEASANT EXPORTS | $131.9K | 10 | 1 | $13.2K |
Venus Remedies Limited ranks #9 among 175 Indian Cytarabine exporters. Average shipment value of $10.4K compared to the market average of $56.0K. The closest competitors by value are UNITED BIOTECH PRIVATE LIMITED and MEDORBIS TRADE LLP.
Which Indian Ports Ship Cytarabine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 249 | 13.6% |
| SAHAR AIR | 242 | 13.3% |
| DELHI AIR | 159 | 8.7% |
| AHEMDABAD AIR ACC (INAMD4) | 145 | 7.9% |
| DELHI AIR CARGO ACC (INDEL4) | 144 | 7.9% |
| AHEMDABAD AIR | 142 | 7.8% |
| MUNDRA SEA (INMUN1) | 139 | 7.6% |
| MUNDRA SEA | 111 | 6.1% |
What Other Advanced Oncology Products Does Venus Remedies Limited Export?
Venus Remedies Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Venus Remedies Limited's Cytarabine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Venus Remedies. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for exports to Europe and the Americas. Such disruptions necessitate strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost-effectiveness.
Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to strengthen their presence in the U.S. market. India now supplies 40% of the U.S.'s generic drug needs, reflecting a growing reliance on Indian manufacturers. (ibef.org) Venus Remedies' recent QIDP designation from the U.S. FDA for VRP-034 positions the company favorably to leverage this opportunity, potentially enhancing its market share in the U.S.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains critical. Venus Remedies' renewal of the EU-GMP certification indicates their proactive approach to meeting stringent EU regulations, thereby ensuring continued access to European markets. (business-standard.com)
Venus Remedies Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for pharmaceutical exporters. Venus Remedies has demonstrated a consistent commitment to quality, as evidenced by multiple GMP certifications. In addition to the EU-GMP renewal, the company secured GMP certification from Moldova's Ministry of Health in January 2025, covering their antibiotic-carbapenem manufacturing facility. (apnnews.com) Furthermore, the renewal of Ukrainian GMP certification in May 2025 for their Baddi facility underscores their adherence to global quality standards. (apnnews.com)
These certifications not only facilitate market access but also enhance the company's reputation as a reliable supplier of high-quality pharmaceuticals. In an industry where regulatory compliance is closely scrutinized, Venus Remedies' proactive measures position them favorably among global competitors.
About Venus Remedies Limited
Venus Remedies Limited exports 29 products worth $86.4M. Beyond Cytarabine, top products include Meropenem, Imipenem, Enoxaparin, Ceftriaxone, Paclitaxel. View the complete Venus Remedies Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Cytarabine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Cytarabine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Venus Remedies Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 18 individual customs records matching Venus Remedies Limited exporting Cytarabine, covering 16 formulations to 7 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 110+ countries, 381+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Cytarabine Export Data from Venus Remedies Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Venus Remedies Limited's Cytarabine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Venus Remedies Limited
Full Company Profile →
29 products · $86.4M total trade · 6 categories
Cytarabine Stats
Company Overview
Top Products by Venus Remedies Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Venus Remedies Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cytarabine. For current shipment-level data, contact TransData Nexus.